# Semaglutide + CBT for Cocaine Use Disorder (Phase 2)

**Type:** Clinical trial  
**Phase:** 2  
**Status:** Recruiting (as of May 2026)  
**Intervention:** Semaglutide combined with cognitive behavioral therapy (CBT)  
**Population:** Adults with diagnosed cocaine use disorder and BMI ≥25  
**Primary objective:** Reduce cocaine cravings and use  
**Registry:** withpower.com/trial/phase-2-cocaine-related-disorders-10-2025

## Timeline

- **2025-10** — Trial opened for recruitment
- **2026-05** — Actively recruiting participants

## Context

This trial follows the All of Us observational finding (Abegaz et al., March 2026) showing 75% lower odds of cocaine use disorder in GLP-1 users (OR=0.25). Cocaine use disorder has no FDA-approved pharmacotherapy, making this a high-priority unmet need. The trial combines semaglutide with CBT, reflecting the behavioral-biological integration model seen in other GLP-1 SUD trials.

## Expected Results

Phase 2 results anticipated 2027-2028.